Recently, Sanofi-Aventis, the world's third-largest pharmaceuticals group, announced in Beijing that it will implement a plan to expand its R&D scale in China, expand its research and development organization in Shanghai, launch the newly-built Beijing Biometrics Center, and cooperate with the Shanghai Life Science Institute of Chinese Academy of Sciences. The institute has signed research cooperation agreements to jointly explore innovative drugs for neurological diseases, diabetes and cancer treatment. On the same day, Sanofi-Aventis held a signing ceremony for a strategic cooperation agreement with the Shanghai Institute of Life Sciences, Chinese Academy of Sciences. Marek, senior vice president of global research and development at Sanofi-Aventis, announced the establishment of the first Chinese research fund to train and honor outstanding people who conduct research in the fields of structural chemistry, biology, and pharmacology. Wu Jiarui, vice president of the Shanghai Institute of Life Sciences, Chinese Academy of Sciences, stated that the cooperation agreement plans to cooperate in the research and development of advanced innovative drugs. This will enhance the level of Chinese medicine research and development, and promote the rapid transformation of basic research results into therapeutic drugs to benefit patients. Jiang Ningjun, vice president of global R&D and president of China's R&D, Sanofi-Aventis, said that he will fully support scientific research to meet the medical needs of patients in China and around the world in order to improve the international competitiveness of drug innovation in China. In another development, Sanofi-Aventis also launched a complete vaccine development project in China. Sanofi-Aventis is increasing its expansion of the Chinese vaccine market. In 2012, the company's influenza vaccine production plant in Shenzhen will be put into operation. By then, Sinon will sell 25 million seasonal influenza vaccines annually in China.
Aluminum Coolers for Compressor, Aluminum plate&bar heat exchangers (oil cooler, air cooler/charge air coolers,compressor coolers, water cooler and combi coolers) have been widely applied for all kinds of compressor including air compressors, LNG-BOG recovery compressor, CNG compressor and more.
Heat Exchanger for Air Dryer, The heat exchangers transfer heat between a cold medium and the damp compressed air. This cools the compressed air to a pressure dew point. If required the condensation generated by the cooling process is collected in a condensation chamber integrated into the heat exchanger and continually drained off.
Advantage:
Compact, Lightweight, High Efficient Heat Transfer
Customize High Quality Aluminum plate-fin cooler upon your drawing, sample or parameter requirement.
FAQ
Q1:Could you customize oil cooler/heat exchanger?
We can manufacture plate-fin heat exchanger/oil cooler /intercooler according to your drawings or samples or parameter requirement.
Q2: I want to buy your products, how can I pay?
A :You can pay via T/T
Q3: How can you guarantee the quality?
A: One year's warranty against B/L date.
Q4: If we don`t find what we want on your website, what should we do?
A: You can email us the descriptions and pictures of the products you need, We will check whether we can make it.
Q5: Can we buy samples of each item for quality testing?
A: Yes, we understand quality test is important and we are glad to send the sample for quality testing.
Q6: What is the lead time?
A: Normal : Plate-fin heat exchanger for 2~3 weeks; Tube&fin or stacked layer coolers for 5 weeks. Exact time upon negotiation
Air Compressor Oil Cooler,CNG Compressor Aluminum Cooler,Compressor Gas Cooler and Radiator Assembly,Compressor Coolers,Charge Air Coolers Wuxi Better Technology Co., Ltd , https://www.btheatexchanger.com
The property market in Beijing, which was once very strong, has also started to decline. In September, the housing price in Beijing fell by 0.2%...
According to Marek, the Group's China Clinical Research Center, established in Shanghai in 2005, conducts various clinical trials with the most stringent quality standards and participates in various compound research projects including Laureate, Rimonabassa, Polyvita, and Rabies Vaccine. The Beijing Biostatistics Center, which was recently completed, will be fully operational by the end of this year. According to reports, the center can provide clinical trial research design, data management and statistical analysis for the world. In cooperation with the Tianjin Institute of Hematology, Chinese Academy of Medical Sciences, we have succeeded in isolating potential cancer stem cells and entering antibody research on cancer stem cells, which is expected to be transformed into drugs for the treatment of leukemia. 
Pharmaceutical giant Sanofi-Aventis plans to expand its research and development in China